Sunovion to acquire Elevation Pharma

Thursday, August 30, 2012 01:42 PM

Sunovion Pharmaceuticals, a Marlborough, Mass.-based pharmaceutical company focused on the central nervous system and respiratory disease, has agreed to acquire San Diego-based Elevation Pharmaceuticals, which specializes in the development of new aerosol therapies for patients with respiratory diseases.

The acquisition includes Elevation Pharmaceuticals' EP-101 product, an inhalation solution of a long-acting muscarinic antagonist (LAMA) bronchodilator that is in phase IIb clinical trials for the treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Sunovion will make an upfront payment of $100 million to the shareholders of Elevation on closing of the acquisition of its shares, and thereafter it will make development milestone payments for EP-101 up to $90 million. Furthermore, after the regulatory approval, Sunovion will also make commercial milestone payments up to $210 million. Subsequent milestone payments up to $30 million could occur contingent upon the successive development of additional new programs.

"Nebulized medicine is an important treatment option for older and sicker patients—the fastest growing segment within COPD," said Bill Gerhart, founder and CEO of Elevation Pharmaceuticals. "Sunovion is the ideal sponsor to realize our original vision to significantly elevate the standard of care for this underserved patient population."

The boards of both Sunovion and Elevation have approved the transaction. The acquisition is subject to customary closing conditions.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs